Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.51 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095407 | 0.90 | DRD4 (0.64) | DRD4HTR1AKCNH2ADRA2CHTR2A | |
| SCHEMBL6095488 | 0.79 | GRM2 (0.50) | DRD4OPRM1DRD3GRM2ALDH1A2 | |
| SCHEMBL7701573 | 0.78 | GRM2 (0.48) | DRD4HTR1AOPRM1ABCB11ADRA2A | |
| SCHEMBL6874013 | 0.78 | DRD4 (0.56) | DRD4HTR1AKCNH2ADRA2CHTR2A | |
| SCHEMBL6096279 | 0.77 | DRD4 (0.76) | DRD4GRM2ALDH1A1DRD2KDM4E | |
| SCHEMBL18658152 | 0.76 | HTT (0.57) | DRD4HTR1AKCNH2ADRA2CHTR2A | |
| SCHEMBL23964164 | 0.75 | DRD4 (0.68) | DRD4HTR1AKCNH2ADRA2CHTR2A | |
| SCHEMBL6095609 | 0.74 | HTT (0.49) | DRD4KCNH2ALDH1A2ALDH1A1ALDH2 | |
| SCHEMBL6095538 | 0.74 | DRD4 (0.48) | DRD4HTR1AOPRM1ABCB11ADRA2A | |
| SCHEMBL4809921 | 0.73 | DRD4 (1.00) | DRD4HTR1AADRA2CHTR2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | claimed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002092575-A1 | BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7030150-B2 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2006-04-18 | — | — | US | disclosed |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142365-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885HTR1A 3692/4885OPRM1 3238/4885 |
| US-20030119754-A1 | Benzimidazole compounds and antiviral uses thereof | MAVS, ZC3HAV1, TIMM13 | DRD4 1827/4885HTR1A 3692/4885OPRM1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.